Working… Menu

APR-246 in Combination With Ibrutinib or Venetoclax-R in Subjects With TP53-Mutant R/R Non Hodgkin Lymphomas (NHL) (R/R)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04419389
Recruitment Status : Recruiting
First Posted : June 5, 2020
Last Update Posted : January 19, 2021
Information provided by (Responsible Party):
Aprea Therapeutics

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : June 2023